Influenza vaccine 2 by Shanghai Institute of Biological Products for Pandemic Influenza: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza vaccine 2 overview
Vaccine is under development for the prevention of infections caused by pandemic influenza virus. The vaccine works by inducing the body’s immune response.
Shanghai Institute of Biological Products overview
Shanghai Institute of Biological Products (SIBP) engaged in production and distribution of bacterial and virus vaccines, toxoids, and analogous products. It serves various markets including medical clinics and hospitals, pharmaceuticals, health information systems, dental and orthodontic practitioners. The company is headquartered in Shanghai, China.
For a complete picture of Influenza vaccine 2’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Influenza #vaccine #Shanghai #Institute #Biological #Products #Pandemic #Influenza #Likelihood #Approval
